BidaskClub cut shares of Myriad Genetics (NASDAQ:MYGN) from a sell rating to a strong sell rating in a report released on Saturday, BidAskClub reports.

Several other research firms have also recently issued reports on MYGN. Zacks Investment Research raised Myriad Genetics from a sell rating to a hold rating and set a $15.00 price objective on the stock in a research report on Thursday, March 26th. Bank of America lowered their price target on Myriad Genetics from $16.00 to $13.00 and set an underperform rating on the stock in a report on Thursday, April 2nd. TheStreet cut Myriad Genetics from a c- rating to a d+ rating in a report on Friday, March 13th. Barclays lowered their price target on Myriad Genetics from $14.00 to $10.00 and set an underweight rating on the stock in a report on Thursday, March 26th. Finally, Needham & Company LLC reissued a hold rating on shares of Myriad Genetics in a report on Wednesday, May 6th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and one has issued a buy rating to the company’s stock. Myriad Genetics currently has a consensus rating of Hold and a consensus price target of $21.16.

MYGN stock opened at $11.02 on Friday. The stock has a market capitalization of $796.99 million, a PE ratio of -5.51 and a beta of 1.30. Myriad Genetics has a 12-month low of $9.24 and a 12-month high of $48.40. The company has a current ratio of 3.14, a quick ratio of 2.87 and a debt-to-equity ratio of 0.29. The stock’s 50 day simple moving average is $13.90 and its 200 day simple moving average is $18.69.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.02 by ($0.10). The business had revenue of $164.00 million during the quarter, compared to the consensus estimate of $167.38 million. Myriad Genetics had a negative net margin of 19.49% and a positive return on equity of 1.95%. The business’s revenue was down 24.4% compared to the same quarter last year. During the same period last year, the company posted $0.46 earnings per share. On average, research analysts predict that Myriad Genetics will post -0.55 earnings per share for the current year.

Several large investors have recently bought and sold shares of the company. State Street Corp increased its stake in shares of Myriad Genetics by 5.4% in the 1st quarter. State Street Corp now owns 4,096,003 shares of the company’s stock worth $58,614,000 after purchasing an additional 209,727 shares in the last quarter. Skandinaviska Enskilda Banken AB publ increased its stake in shares of Myriad Genetics by 17.4% in the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 103,100 shares of the company’s stock worth $1,475,000 after purchasing an additional 15,300 shares in the last quarter. FDx Advisors Inc. purchased a new stake in shares of Myriad Genetics in the 1st quarter worth $300,000. HighTower Advisors LLC increased its stake in shares of Myriad Genetics by 70.0% in the 1st quarter. HighTower Advisors LLC now owns 21,160 shares of the company’s stock worth $304,000 after purchasing an additional 8,711 shares in the last quarter. Finally, Voloridge Investment Management LLC purchased a new stake in shares of Myriad Genetics in the 1st quarter worth $432,000. Hedge funds and other institutional investors own 99.05% of the company’s stock.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Featured Article: Trading Ex-Dividend Strategy

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.